If you have been reading about visceral fat and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
=== Third wave (2013–2016) === According to the CDC, the third wave of the opioid epidemic began in 2013, and concluded in 2016. This wave coincided with a significant increase in overdose deaths involving synthetic opioids, particularly illegally produced fentanyl. During this period, deaths related to prescription opioids increased marginally, while heroin-related deaths remained relatively stable. The demographic affected during this wave was younger, less frequently male, and more likely to be white and rural compared to the previous waves. The third wave also witnessed an increase in opioid-related overdoses among Black and Hispanic individuals in urban areas who use drugs. The rise in fentanyl-related deaths is attributed to the fact that fentanyl is 50 to 100 times more potent than morphine, and it is often mixed into heroin or cocaine to increase potency at a low cost. Considering that Black Americans tend to consume cocaine more frequently than heroin or other prescription opioids compared to white populations, the increase in deaths is linked to the greater prevalence of fentanyl-laced cocaine.
The δ13C of the emu's diet is reflected in the δ13C of the calcite of its egg shell. Small stones are swallowed to assist in the grinding up and digestion of the plant material. Individual stones may weigh 45 g (1.6 oz) and the birds may have as much as 745 g (1.642 lb) in their gizzards at one time. They also eat charcoal, although the reason for this is unclear. Captive emus have been known to eat shards of glass, marbles, car keys, jewellery and nuts and bolts. Emus drink infrequently but ingest large amounts when the opportunity arises. They typically drink once a day, first inspecting the water body and surrounding area in groups before kneeling down at the edge to drink. They prefer being on firm ground while drinking, rather than on rocks or mud, but if they sense danger, they often stand rather than kneel. If not disturbed, they may drink continuously for ten minutes. Due to the scarcity of water sources, emus are sometimes forced to go without water for several days. In the wild, they often share water holes with other animals such as kangaroos; they are wary and tend to wait for the other animals to leave before drinking.
Bursty: Data transfer is abrupt and does not include content such as video, audio, or other isochronous forms of data. Light: For most applications, packet sizes are limited to 256 bytes. Transmission of multiple consecutive packets may occur, but is generally avoided, if possible. Asynchronous: DASH7's main method of communication is by command–response, which by design requires no periodic network "hand-shaking" or synchronization between devices. Stealth: DASH7 devices do not need periodic beaconing to be able to respond in communication. Transitive: A DASH7 system of devices is inherently mobile or transitional. Unlike other wireless technologies, DASH7 is upload-centric, not download-centric, thus devices do not need to be managed extensively by fixed infrastructure, i.e., base stations.
Sources: en.wikipedia.org
=== Inter-method variability === The following table illustrates variability in reference ranges of serum prolactin between some commonly used assay methods (as of 2008), using a control group of healthy health care professionals (53 males, age 20–64 years, median 28 years; 97 females, age 19–59 years, median 29 years) in Essex, England:
The main player in the catalytic mechanism in the serine proteases is the catalytic triad. The triad is located in the active site of the enzyme, where catalysis occurs, and is preserved in all superfamilies of serine protease enzymes. The triad is a coordinated structure consisting of three amino acids: His 57, Ser 195 (hence the name "serine protease") and Asp 102. These three key amino acids each play an essential role in the cleaving ability of the proteases. While the amino acid members of the triad are located far from one another on the sequence of the protein, due to folding, they will be very close to one another in the heart of the enzyme. The particular geometry of the triad members are highly characteristic to their specific function: it was shown that the position of just four points of the triad characterize the function of the containing enzyme. In the event of catalysis, an ordered mechanism occurs in which several intermediates are generated. The catalysis of the peptide cleavage can be seen as a ping-pong catalysis, in which a substrate binds (in this case, the polypeptide being cleaved), a product is released (the C-terminus "half" of the peptide with amino group visible), another substrate binds (in this case, water), and another product is released (the N-terminus "half" of the peptide with carboxyl group visible). Each amino acid in the triad performs a specific task in this process:
==== No Más Bebes (2015) ==== The film No Más Bebes tells the stories of several Chicana women sterilized at the Los Angeles County-USC Medical Center in the 1970s. They were part of a larger group of women who underwent sterilization without a proper form of consent. Many women only learned of their sterilization months and perhaps years later. Antonia Hernandez, the plaintiff's attorney in the Madrigal v. Quilligan (1978) lawsuit, is largely responsible for relaying such information, as she spent significant amounts of time patrolling Mexican American barrios searching for Chicana women listed on hospital documents. Hernandez and Charles Nabarette learned of the coerced tubal ligations from Dr. Bernard Rosenfeld, a resident at the teaching hospital. In the documentary, he compares the medical center's practices to the sterilization of Jews in Nazi Germany at the beginning of World War II. Consequently, he was terminated for acting as a whistleblower, and nearly at risk of losing his medical license. The ten women who filed the lawsuit were U.S. citizens with varying proficiencies in the English language. The film reveals many justifications for the tubal ligations performed, including rushed, last-minute decision-making, misunderstanding of medical jargon, language barriers, and written signatures of consent. Dr. Edward James Quilligan, the main defendant on trial, claims that the hospital was simply “practicing good medicine” in one of his interviews for the documentary.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.